Vera Therapeutics is trading at $33.50 (+6.08%) after reporting second-quarter EPS of -$1.52 versus the -$1.60 analyst expectation.
- Began the TRUTAKNA commercial launch.
- Management highlighted $499.2 million in liquidity and expects third-quarter efficacy data to support a supplemental FDA filing in Q4 2026.
- The gain follows the August 10 earnings release; Wedbush lowered its price target to $34 from $43.